Ondrej Fiala1, Milos Pesek2, Jindrich Finek3, Marek Minarik4, Lucie Benesova5, Ondrej Sorejs3, Martin Svaton2, Zbynek Bortlicek6, Radek Kucera7, Ondrej Topolcan7. 1. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic fiala.o@centrum.cz. 2. Department of Pneumology, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic. 3. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic. 4. Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic Department of Analytical Chemistry, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic. 5. Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic. 6. Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 7. Department of Nuclear Medicine, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
Abstract
BACKGROUND: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. PATIENTS AND METHODS: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. RESULTS: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. CONCLUSION: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC. Copyright
BACKGROUND: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. PATIENTS AND METHODS: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. RESULTS:EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. CONCLUSION:EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC. Copyright